Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The World Health Organisation (<keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords">WHO</keyword>) has announced that <keyword id="22989608" type="General" weightage="100" keywordseo="M-Pox" source="keywords">M-Pox</keyword> will continue to be classified as a <keyword id="21952478" type="General" weightage="20" keywordseo="public-health-emergency" source="keywords">public health emergency</keyword> of international concern (PHEIC), citing a resurgence in cases and the virus's ongoing geographic spread. The high-alert status initially declared in August, was reaffirmed following a meeting of the WHO Emergency Committee, The Express Tribune reported on Friday. The decision comes as M-Pox cases surge, particularly with the spread of the <keyword id="22875864" type="General" weightage="20" keywordseo="clade-Ib-variant" source="keywords">clade Ib variant</keyword> beyond its origin in the Democratic Republic of Congo to neighbouring African nations, Europe, and Asia. "Rising case numbers, the continuing geographic spread, and the need for a cohesive response have made it essential to maintain this emergency status," the WHO said in its statement. Confirmed cases of clade Ib have been detected in the United Kingdom, Germany, Sweden, and India, highlighting the global scale of the outbreak, reported The Express Tribune. M-Pox, a viral disease transmitted through close contact, presents flu-like symptoms and lesions. Although typically mild, it can be fatal, particularly in regions with inadequate healthcare. Over 46,000 suspected cases have been reported this year in Africa, with Congo accounting for the majority of the more than 1,000 suspected deaths. The new PHEIC declaration underscores the global threat posed by clade Ib and follows earlier alerts related to a separate strain during the 2022-2023 outbreak. In response to growing concerns, the WHO has expanded vaccine authorisations. Bavarian Nordic's <keyword id="24137585" type="General" weightage="20" keywordseo="M-Pox-vaccine" source="keywords">M-Pox vaccine</keyword> was approved earlier this year, with Japan's KM Biologics' vaccine added to the list of emergency-use vaccines in September. WHO officials have faced criticism for delays in <keyword id="21847727" type="General" weightage="20" keywordseo="vaccine-distribution" source="keywords">vaccine distribution</keyword> but stressed that vaccination remains a cornerstone of global response efforts, The Express Tribune reported. "The emergency status underscores the urgency to mount a unified global response," a WHO spokesperson stated. The organisation urged countries and health partners to collaborate on widespread vaccination campaigns and enhance public awareness to curb the virus's spread effectively.

M-Pox remains public health emergency: WHO

Sydney, Aug 15 (The Conversation): The <keyword id="19896311" type="General" weightage="20" keywordseo="World-Health-Organization" source="keywords" meta.keywordsubtype="org" meta.entityname="World Health Organization" meta.hostid="261" meta.entityid="World Health Organization">World Health Organization</keyword> (<keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords">WHO</keyword>) has declared <keyword id="20965747" type="General" weightage="100" keywordseo="mpox" source="keywords">mpox</keyword> a public health emergency of international concern, after rising cases in the <keyword id="22796094" type="General" weightage="20" keywordseo="Democratic-Republic-of-the-Congo" source="keywords">Democratic Republic of the Congo</keyword> and the potential for further spread. This now triggers a coordinated international response to an extraordinary event and the mobilisation of resources, such as vaccines and diagnostic testing, to curb the spread of this infectious disease. But WHO has not declared mpox a <keyword id="19913581" type="General" weightage="20" keywordseo="pandemic" source="keywords">pandemic</keyword>. Rather, the measures it has triggered are designed to prevent it from becoming one. <h2>What triggered this latest alert?</h2> Mpox, once known as monkeypox, is a viral infection closely related to <keyword id="22362924" type="General" weightage="20" keywordseo="smallpox" source="keywords">smallpox</keyword>. Initial symptoms include a fever, headache, swelling of the lymph nodes and muscle ache. A typical rash follows, mainly on the face, hands and feet. The spread of mpox through certain African countries led the Africa Centres for Disease Control and Prevention to declare earlier this week mpox a public health emergency of continental security. This is the first time the organisation has issued such an alert since it was established in 2017. The situation in the Democratic Republic of the Congo in central Africa has been particularly worrying for more than a year. There are two types or clades of mpox. Clade II, which originates in west Africa, is less severe. It has a fatality rate of up to 1 per cent (in other words, roughly one in 100 are expected to die from it). But clade I, from central Africa, has a fatality rate of up to 10 per cent (up to one in ten die). This compares to a 0.7 per cent fatality rate for the Omicron variant of SARS-CoV-2, the virus that causes COVID. The Democratic Republic of the Congo is seeing large epidemics of the more deadly clade I mpox. Mpox is endemic in some parts of central and west Africa, where the virus exists in animals and can spread to humans. Outbreaks have been increasing, with more human-to-human spread, since 2017. This is partly due to very low levels of immunity to the mpox virus, which is related to the virus that causes smallpox. Mass vaccination against smallpox ceased more than 40 years ago globally, resulting in minimal immunity in populations today against mpox. The WHO designation announced this week relates to the clade I. Not only does this have a higher fatality rate, it has new mutations that enhance spread between people. These changes, and the global lack of immunity to mpox, makes the world's population vulnerable to the virus. <h2>There are two different epidemics</h2> In 2022, an epidemic of mpox swept through non-endemic countries, including beyond Africa. This was a variant of clade II originating from Nigeria, called clade IIb. This was sexually transmitted, predominantly affecting men who have sex with men, and had a low fatality rate. That epidemic peaked in 2022, with vaccines made available to people at risk in high-income countries, but there has been an uptick in 2024. At the same time, large clade I epidemics were occurring in the Democratic Republic of the Congo, but with far less attention. Vaccines were not available there, even in 2023, when there were 14,626 cases and 654 deaths. Mortality was 4.5 per cent, and higher in children. In fact, most cases and deaths in the Democratic Republic of the Congo have been children. This means most transmission there is non-sexual and is likely to have occurred through close contact or respiratory aerosols. However, in 2023 an <keyword id="20877025" type="General" weightage="20" keywordseo="outbreak" source="keywords">outbreak</keyword> in a non-endemic part of the country, South Kivu in the east, appeared to be by sexual transmission, indicating more than one epidemic and different transmission modes in the Democratic Republic of the Congo. By mid-2024, there were already more cases in the country than all of 2023 - more than 15,600 cases and 537 deaths. Testing capacity is low in the Democratic Republic of the Congo, most cases are not confirmed by lab testing, and the data we have are from a small sample of genomic sequences from the Kamituga region of South Kivu. This show mutations to the clade I virus around September 2023, to a variant termed clade Ib, which is more readily transmissible between people. We do not have much data to compare these viruses with the viruses causing cases in the rest of the country. <h2>Mpox is spreading internationally</h2> In the past month, the virus has spread to countries that share a border with the Democratic Republic of the Congo - Rwanda and Burundi. It has also spread to other east African countries, such as Kenya and Uganda. None of these countries have had mpox cases previously. In an interconnected, mobile world, cases may spread to other continents, as mpox did in 2018 from Nigeria to the United Kingdom and other countries. A few travel-related cases between 2018 and 2019 may have led to the large multi-country 2022 clade IIb epidemic. <h2>We have vaccines, but not where they are needed</h2> As the mpox virus and smallpox viruses are related (they are both orthopoxviruses), smallpox vaccines offer protection against mpox. These vaccines were used to control the 2022 clade IIb epidemic. However, most of the world has never been vaccinated, and has no immunity to mpox. The newer <keyword id="19959412" type="General" weightage="20" keywordseo="vaccine" source="keywords">vaccine</keyword> (called Jynneos in some countries and Imvamune or Imvanex in others) is effective. However, supplies are limited, and vaccine is scarce in the Democratic Republic of the Congo. WHO's declaration of mpox as a public health emergency of international concern will help mobilise vaccines to where they are needed. The Africa Centres for Disease Control had already begun negotiations to secure 2,00,000 doses of vaccine, which is a fraction of what is required to control the epidemic in the Democratic Republic of the Congo. <h2>What happens now?</h2> Ultimately, a serious epidemic anywhere in the world is a concern for all of us, as it can spread globally through travel, as we saw with the COVID pandemic. Controlling it at the source is the best measure, and WHO's latest declaration will help mobilise the required resources. Surveillance for spread of this more serious version of mpox is also essential, bearing in mind that many countries do not have the capacity for widespread testing. So we'll have to rely on "suspected cases", based on a clinical definition, to keep track of the epidemic. Open-source epidemic intelligence - such as using AI to monitor trends in rash and fever illness - can also be used as an early warning system in countries with weak health systems or delayed reporting of cases. A further complication is that 20-30 per cent of people with mpox may simultaneously have chickenpox, an unrelated infection that also causes a rash. So an initial diagnosis of chickenpox (which is easier to test for) does not rule out mpox. Effective communication and tackling push-back against public health measures and disinformation is also key. We saw how important this was during the COVID pandemic. Now, WHO will coordinate the global mpox response, focusing on equity in disease prevention and access to diagnostics and vaccines. It is up to individual countries to do their best to comply with the International Health Regulations, and the protocols for how such a global emergency are managed.

WHO has declared mpox a global health emergency. What happens next?

The <keyword id="22667872" type="General" weightage="100" keywordseo="mpox-outbreak" source="keywords">mpox outbreak</keyword> in <keyword id="19924003" type="General" weightage="20" keywordseo="africa" source="keywords">Africa</keyword> is yet another example of how <keyword id="20040661" type="General" weightage="20" keywordseo="infectious-diseases" source="keywords">infectious diseases</keyword>, perceived to be "someone else's problem", and affecting mainly poor, developing countries, may suddenly pose unexpected global threats. Other examples of <keyword id="22817243" type="General" weightage="20" keywordseo="neglected-diseases" source="keywords">neglected diseases</keyword> include the West Nile, Zika and Chikungunya viruses. Mpox was discovered in 1958 (in captive monkeys, hence the original misnomer "monkeypox") and the first human case was identified in 1970. Then, for decades it was largely neglected by the scientific and public health communities, regarded as an uncommon infection in remote rural areas in tropical Africa, without relevance for the rest of the world. When a massive mpox outbreak hit developed countries in 2022, increased research funding led to a surge in scientific studies. On just one medical search engine, there's been more research produced since April 2022 than in the preceding 60 years. The 2022-23 global mpox outbreak happened despite repeated calls from African researchers for increased global investment in diagnostic, therapeutic and infection prevention tools for mpox. The WHO has now declared the current upsurge of mpox in central Africa a <keyword id="21952478" type="General" weightage="20" keywordseo="public-health-emergency" source="keywords">public health emergency</keyword> of international concern. This is the highest alert level for events that constitute a public health risk to other countries and requires a coordinated international response. Mpox's recent history is yet another reminder that an infectious disease in one corner of the world should not be regarded as someone else's problem, as it can suddenly start to spread fast and far. It also highlights global inequities in resource allocation and access to vaccines, diagnostics and treatments. These were made available in many industrialised countries and helped curb the global outbreak, but are still largely lacking in most of Africa. <h2>The 2022 outbreak: a total surprise</h2>The disease has been renamed "mpox" but the name of the virus, for now, remains "monkeypox" (MPXV). It is closely related to the smallpox virus. MPXV was considered a <keyword id="21311828" type="General" weightage="20" keywordseo="zoonotic-disease" source="keywords">zoonotic disease</keyword> endemic in parts of central and west Africa. It was acquired mainly through close contact with wild mammals, especially handling bush meat, but there was no sustained human-to-human transmission. Only very occasionally were cases seen outside the endemic areas, due to infected travellers or import of infected small mammals. This changed abruptly in 2022: a massive, rapidly evolving global outbreak caused over 99,000 laboratory-confirmed cases in 116 countries. At its peak in August 2022, over 6,000 cases were reported each week. This outbreak came as a total surprise: most cases were reported from non-endemic countries, mostly in men who have sex with men, who had become infected during recent sexual encounters. Even though most cases were clinically not particularly severe and the death toll stands at just over 200, the global outbreak was declared a public health emergency of international concern by the <keyword id="19896311" type="General" weightage="20" keywordseo="world-health-organization" source="keywords">World Health Organization</keyword> on 23 July, 2022. Fortunately, case numbers soon plummeted due to a combination of behavioural changes and vaccination in at-risk groups. Modern vaccines and antiviral drugs with activity against mpox were made available in many affected high-income countries. These had been developed and stockpiled in the US and Europe, mostly in preparation for a potential bioweapon attack using a poxvirus. The global outbreak in 2022 was caused by clade II of MPXV, which is endemic in west Africa and not as virulent as clade I MPXV, which so far has only been seen in the Congo Basin. That first mpox public health emergency of international concern was declared over in May 2023. Clade II MPXV infections are still occurring globally, but the worst seems over - for now. Complacency would be misguided, as illustrated by the current mpox outbreak that is gathering steam. <h2>Upsurge in Africa</h2>The African region is experiencing an upsurge in mpox cases, which started in 2023. As the continent which includes the areas where mpox has been endemic for a long time, Africa now presents a complex mosaic. The current clade I MPXV (formerly called Congo Basin strain) is more virulent than the clade II (west African) strain, resulting in a higher case fatality rate. The ongoing outbreak has its epicentre in South Kivu province, eastern DRC, and has the potential to fuel a large pandemic. It has a distinct epidemiological pattern with sustained chains of human-to-human transmission, often via the sexual route. It may have increased transmissibility (we don't know yet). The virus which causes it is the newly defined clade Ib lineage. It displays mutations that are the hallmark of human-to-human spread that is estimated to have been happening since September 2023. Case numbers are rising rapidly, even though many suspected cases are likely not tested and thus not counted as confirmed. Complicating matters, a commonly used test was found to miss infections with this lineage of the virus. It affects mostly adults. The case fatality rate is higher than it was in the 2022 global outbreak. Already, this outbreak has resulted in mpox cases occurring in several neighbouring countries, including some (like Kenya), with no previous record of mpox. The challenge is enormous. The eastern DRC is an area beset by multiple problems. This includes natural disasters, violence and infectious diseases including measles, cholera and poliomyelitis for the DRC. In recent years the second-largest Ebola outbreak ever took place in the wider area and, despite the availability of vaccines and treatments, posed considerable challenges. <h2>What needs to happen</h2>Equitable access to diagnostic tests, vaccines and antiviral treatments requires political commitment and financial investments. Scientific investigations are needed to learn more about exposure settings, transmission routes and clinical presentations. It's important to find the best ways to make these interventions. There is no doubt that a disease in one corner of the world can suddenly become a global heath threat. It's time the global health system woke up to this reality.

Mpox outbreak in Africa was neglected - it could now turn into the next global pandemic

<keyword id="19894886" type="General" weightage="20" keywordseo="china" source="keywords">China</keyword>'s top drug regulator has cleared a mpox vaccine developed by local drug firm Sinopharm for clinical trials which could be the country's first experimental dose to battle the deadly disease. The domestic vaccine candidate, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is expected to play an important role in preventing and controlling mpox infections, the company said in a statement released on Monday afternoon. There is currently no approved mpox vaccine in China. Globally, a few vaccines have been approved in the United States, Canada, the European Union, Japan and Russia. In China, a vaccine candidate typically goes through three phases of clinical trials before gaining market approval. The process can take years, even decades. However, the National Medical Products Administration, China's top drug regulator, has launched a number of accelerated or streamlined channels to facilitate applications of novel drugs and vaccines or those in urgent need, state-run China Daily reported on Tuesday. According to the company, the new vaccine is a replication-deficient vaccine based on a strain called MVA. The description is the same as <keyword id="22925756" type="General" weightage="20" keywordseo="jynneos" source="keywords">Jynneos</keyword>, the world's first mpox vaccine approved by the <keyword id="20256595" type="General" weightage="20" keywordseo="food-and-drug-administration" source="keywords">Food and Drug Administration</keyword> in the United States in 2019. The <keyword id="19902256" type="General" weightage="20" keywordseo="world-health-organisation" source="keywords">World Health Organisation</keyword> said on August 14 that the mpox outbreak in <keyword id="19924003" type="General" weightage="20" keywordseo="africa" source="keywords">Africa</keyword> constitutes a public health emergency of international concern - its highest form of alert. Previously, in July 2022, the WHO declared a global emergency but then lifted it in May last year because of a sustained decline in international cases. So far, more than 120 countries and regions across the world have reported more than 100,000 confirmed infections and 226 related deaths. China reported its first imported case in September 2022 and the first domestic case in June last year. By the end of July, the nation had reported 2,567 confirmed cases, according to the China Daily report. SEE ALSO: <a href="https://www.businessinsider.in/business/auto/news/ather-energy-looks-to-raise-3100-crore-files-ipo-papers-with-sebi/articleshow/113214971.cms">Ather Energy looks to raise ₹3,100 crore, files IPO papers with SEBI</a> <a href="https://www.businessinsider.in/tech/mobile/news/iphone-16-pro-iphone-16-pro-max-india-price-specifications/articleshow/113204340.cms">iPhone 16 Pro and iPhone 16 Pro Max with bigger displays, A18 Pro chipset launched starting at ₹1,19,900</a> <a href="https://www.businessinsider.in/tech/mobile/news/apple-iphone-16-iphone-16-plus-price-specs/articleshow/113203568.cms">iPhone 16, iPhone 16 Plus with A18 chipset launched starting at ₹79,900</a>

China's drug regulator clears mpox vaccine; to undergo clinical trial

<ul class="summary-list"><li>Danish monkeypox-vaccine maker Bavarian Nordic surged as much as 17% on Thursday.</li><li>The company's two-day gain extended to 31% at highs after the WHO declared mpox a public health emergency.</li></ul>Danish monkeypox-vaccine maker <a target="_blank" class="" href="https://markets.businessinsider.com/news/bvnkf">Bavarian Nordic</a> surged as much as 17% on Thursday amid rising alarm over the virus.The company extended its two-day gain to 31% at intraday highs after the World Health Organization declared the virus a public health emergency of international concern, citing the rising risk that its outbreak in Africa could spread globally.<a target="_blank" href="https://africa.businessinsider.com/local/lifestyle/who-declares-monkeypox-a-global-emergency/jvln09g">Reports emphasize</a> the need for vaccinations to combat this fast-spreading disease, though supply appears to be constrained.In an <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-08-14/bavarian-nordic-says-it-can-meet-mpox-shot-demand-awaits-orders">interview with Bloomberg</a>, Bavarian Nordic CEO Paul Chaplin noted that the company will be able to meet the challenge among African nations, and pledged to provide 10 million mpox doses to the region by the end of 2025."We have inventory and we have the capabilities. What we're missing are the orders," he said Wednesday, noting that 300,000 doses are ready for shipping.During <a target="_blank" class="" href="https://www.businessinsider.com/heres-how-the-us-handled-its-first-ever-monkeypox-outbreak-2022-5">2022's outbreak</a>, Bavarian Nordic was <a target="_blank" href="https://www.bloomberg.com/news/articles/2022-08-17/monkeypox-vaccine-maker-no-longer-certain-it-can-meet-demand">the only company</a> approved to create a mpox vaccine. However, overwhelming demand forced it to consider outsourcing production.Momentum around the latest emergency announcement has also swept up other firms. In Japan, medical tools supplier Precision System Science rocketed as high as 39% on Wednesday.Chinese firms focused on virus detection products also gained, with Shanghai ZJ Bio-Tech rising as much as 8.4%. Others, such as Daan Gene and Assure Tech Hangzhou, beat the benchmark CSI 300 index.Even before the WHO's declaration, alarm bells have been ringing over the mpox strain that first appeared in September. According to Bloomberg, its broken out in at least six African nations, infecting 15,000.In June, a University of Rwanda lecturer <a target="_blank" class="" href="https://www.businessinsider.com/new-monkeypox-mpox-virus-global-outbreak-risk-2024-7">called it</a> "undoubtedly the most dangerous of all the known strains of mpox."

Danish monkeypox-vaccine maker surges 17% after global health emergency declared

<ul class="summary-list"><li>A new strain of <a target="_blank" href="https://www.businessinsider.com/er-doctor-monkeypox-patients-are-getting-misdiagnosed-with-other-conditions-2022-8">monkeypox virus</a> is "the most dangerous" yet and could be a global threat, experts say.</li><li>The new clade Ib virus emerged in the Democratic Republic of the Congo and spread to Rwanda's border.</li></ul>A deadly and fast-spreading new strain of mpox, <a target="_blank" href="https://www.businessinsider.com/monkeypox-pictures-patient-shares-images-describes-intense-pain-2022-8">the disease caused by the monkeypox virus</a>, has global health officials ringing alarm bells.The new virus is "undoubtedly the most dangerous of all the known strains of mpox," John Claude Udahemuka, a lecturer at the University of Rwanda, said in a press briefing on June 25. He said the virus has caused miscarriages and blindness.An earlier, milder form of mpox — called clade IIb — circulated worldwide in 2022, ultimately <a target="_blank" href="https://www.businessinsider.com/heres-how-the-us-handled-its-first-ever-monkeypox-outbreak-2022-5">infecting more than 32,000 people in the US</a> and killing 58 of them. It prompted the World Health Organization to declare a public health emergency, which ended last year.The new virus is called clade Ib, since it's a <a target="_blank" href="https://www.businessinsider.com/woman-hiv-had-coronavirus-216-days-virus-mutated-2021-6">mutation</a> of an even earlier form of mpox. It first appeared in a remote region of the Democratic Republic of the Congo in September and has spread to towns along the Rwanda border, near Burundi and Uganda.The new clade Ib virus could cause a <a target="_blank" href="https://www.businessinsider.com/bird-flu-avian-influenza-outbreak-us-h5n1-wiping-out-everything-2023-4">global outbreak</a>, experts fear, though they stopped short of warning of a pandemic."The pandemic question is difficult," Trudie Lang, director of the Global Health Network at Oxford University, said in the briefing."I think we need to be really vigilant now and move to try and contain this as quickly as possible in this region," she added. "There's definitely the opportunity for this to get on an airplane."<h2 id="ef566fbb-abea-4b10-aabf-9d64faaf238f">The new mpox strain spreads easily </h2>Mpox spreads through close contact, especially skin-to-skin contact. It can cause flu-like symptoms and a <a target="_blank" href="https://www.businessinsider.com/monkeypox-rash-pictures-when-to-get-checked-2022-5">painful or itchy rash</a> that develops into puss-filled blisters, lesions, and eventually scabs.<div type="image" title="Monkeypox palm of hands" height="459" width="700" msid="111468793" hostid="261" sizebytes="24580"></div><a target="_blank" href="https://www.businessinsider.com/monkeypox-man-hospitalized-couldnt-swallow-spit-feared-death-symptoms-2022-7">Previous strains of the virus</a> have had limited transmission abilities. The clade I virus that's long circulated in the DRC has been mostly associated with spread through families and within households, Land said. The clade IIb virus that went global was mostly sexually transmitted and mostly affected men who have sex with men.The new clade Ib strain seems to do it all.It began spreading through sexual transmission, via the local sex work industry, according to the researchers. However, they said the new virus has also spread within households, between mothers and their children, and there have even been cases of person-to-person spread outside households and without sexual contact.That's "incredibly worrying," Lang said. That's because it has more opportunities to spread than previous strains did.The clade I form of the virus, from which the new strain has emerged, is also more deadly than clade II. According to <a target="_blank" href="https://www.cdc.gov/poxvirus/mpox/about/index.html">WHO</a>, some outbreaks have killed up to 10% of sick people.<h2 id="b8b424dd-af4a-4193-a5ac-002f109faf5a">Researchers only see 'the tip of the iceberg'</h2>It's not yet clear just how deadly the new clade Ib virus is, because researchers aren't sure how many cases there are.Leandre Murhula Masirika, a research coordinator in the local DRC health department, said in the briefing that they had identified more than 600 cases so far."These are the severe cases that make it to hospital, so this will be the tip of the iceberg," Lang said.The WHO's technical lead for mpox, Rosamund Lewis, also raised the alarm last week, saying "There is a critical need to address the recent surge in mpox cases in Africa," according to <a target="_blank" href="https://www.reuters.com/business/healthcare-pharmaceuticals/who-scientists-warn-mpox-strain-congo-2024-06-25/">Reuters</a>.The researchers said they need to better understand the virus to identify the right safety measures and vaccines to contain its spread."We need to first carry out studies of serology and immunology in order to see what kind of vaccination we can propose," Murhula Masirika said.He added that, in the meantime, he wants to give the smallpox vaccine to local sex workers and healthcare workers in hopes that it will confer some immunity to mpox.

You Searched For "mpox health emergency" and got 6 results

M-Pox remains public health emergency: WHO

ANI

WHO has declared mpox a global health emergency. What happens next?

PTI

Mpox outbreak in Africa was neglected - it could now turn into the next global pandemic

PTI

China's drug regulator clears mpox vaccine; to undergo clinical trial

PTI

Danish monkeypox-vaccine maker surges 17% after global health emergency declared

Filip De Mott

Experts are racing to contain 'the most dangerous' monkeypox virus yet before it causes a global outbreak

Morgan McFall-Johnsen

Popular Keywords

Buying Guides